Visfatin/PBEF/Nampt and resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans

Hormone and Metabolic Research

Volumn 42, Issue 4, 2010, Pages 268-273

  Laudes, M ^a   Oberhauser, F ^a   Schulte, D M ^a   Freude, S ^a   Bilkovski, R ^a   Mauer, J ^a   Rappl, G ^a   Abken, H ^a   Hahn, M ^b   Schulz, O ^a   Krone, W ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Atherosclerosis; Inflammation; Insulin resistance

Indexed keywords

ADIPOCYTOKINE; CD14 ANTIGEN; GLITAZONE DERIVATIVE; GLUCOSE; INSULIN; LONG ACTING INSULIN; METFORMIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN; RNA; SHORT ACTING DRUG; SULFONYLUREA;

ADULT; ANTHROPOMETRY; ARTICLE; BLOOD SAMPLING; CELL SELECTION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ANTHROPOMETRY; ANTIGENS, CD14; CYTOKINES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE; HUMANS; INFLAMMATION; INSULIN; MALE; MIDDLE AGED; MONOCYTES; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY; RESISTIN;

EID: 77950493732     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0029-1243638     Document Type: Article

References (40)

1. Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW. Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab 2009 94 1853-1878
2. Katagiri H, Yamada T, Oka Y. Adiposity and cardiovascular disorders: disturbance of the regulatory system consisting of humoral and neuronal signals. Circ Res 2007 101 27-39
3. Yamagishi S, Nakamura K, Matsui T, Takenaka K, Jinnouchi Y, Imaizumi T. Cardiovascular disease in diabetes. Mini Rev Med Chem 2006 6 313-318
4. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, Kitazawa S, Miyachi H, Maeda S, Egashira K, Kasuga M. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006 116 1494-1505
5. Tilg H, Moschen AR. Inflammatory mechanism in the regulation of insulin resistance. Mol Med 2008 14 222-231
6. Gerrity RG, Naito HK, Richardson M, Schwartz CJ. Dietary induced atherogenesis in swine. Morphology of the intima in prelesion stages. Am J Pathol 1979 95 775-792
7. Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, Davis V, Gutierrez-Ramos JC, Connelly PW, Milstone DS. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001 107 1255-1262
8. Byrne GI, Kalayoglu MV. Chlamydia pneumoniae and atherosclerosis: links to the disease process. Am Heart J 1999 138 488-490
9. Laudes M, Oberhauser F, Bilkovski R, Schubert M, Udelhoven M, Wassmer G, Roth B, Krone W. Human fetal adiponectin and retinol-binding protein (RBP)-4 levels in relation to birth weight and maternal obesity. Exp Clin Endocrinol Diabetes 2009 117 146-149
10. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994 372 425-432
11. La Cava A, Alviggi C, Matarese G. Unraveling the multiple roles of leptin in inflammation and autoimmunity. J Mol Med 2004 82 4-11
12. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994 14 1431-1437
13. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T. Association between plasma visfatin/PBEF/Nampt and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 2007 56 451-458
14. Böttcher Y, Teupser D, Enigk B, Berndt J, Klöting N, Schön MR, Thiery J, Blher M, Stumvoll M, Kovacs P. Genetic variation in the visfatin/PBEF/Nampt gene (PBEF1) and its relation to glucose metabolism and fat-depot-specific messenger ribonucleic acid expression in humans. J Clin Endocrinol Metab 2006 91 2725-2731
15. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 2001 409 307-312
16. Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, Manabe I, Utsunomiya K, Nagai R. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 2004 314 415-419
17. Ayoub SS, Botting RM, Joshi AN, Seed MP, Colville-Nash PR. Activation of macrophage peroxisome proliferator-activated receptor-gamma by diclofenac results in the induction of cyclooxygenase-2 protein and the synthesis of anti-inflammatory cytokines. Mol Cell Biochem 2009 327 101-110
18. Laudes M, Bilkovski R, Oberhauser F, Droste A, Gomolka M, Leeser U, Udelhoven M, Krone W. Transcription Factor FBI-1 acts as a dual regulator in adipogenesis by coordinated regulation of cyclin A and E2F-4. J Mol Med 2008 86 597-608
19. Yamagata S, Tomita K, Sato R, Niwa A, Higashino H, Tohda Y. Interleukin-18-deficient mice exhibit diminished chronic inflammation and airway remodelling in ovalbumin-induced asthma model. Clin Exp Immunol. 2008 154 295-304
20. Lazar MA. Resistin- and obesity-associated metabolic diseases. Horm Metab Res 2007 39 710-716
21. Wang T, Zhang X, Bheda P, Revollo JR, Imai S, Wolberger C. Structure of Nampt/PBEF/visfatin/PBEF/Nampt, a mammalian NAD+ biosynthetic enzyme. Nat Struct Mol Biol 2006 13 661-662
22. Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 2004 279 50754-50763
23. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, Tilg H. Visfatin/PBEF/Nampt, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007 178 1748-1758
24. Nowell MA, Richards PJ, Fielding CA, Ognjanovic S, Topley N, Williams AS, Bryant-Greenwood G, Jones SA. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 2006 54 2084-2095
25. Otero M, Lago R, Gomez R, Lago F, Dieguez C, Gmez-Reino JJ, Gualillo O. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin/PBEF/Nampt in patients with rheumatoid arthritis. Ann Rheum Dis 2006 65 1198-1201
26. Oki K, Yamane K, Kamei N, Nojima H, Kohno N. Circulating visfatin/PBEF/Nampt level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol (Oxf) 2007 67 796-800
27. Xie H, Tang SY, Luo XH, Huang J, Cui RR, Yuan LQ, Zhou HD, Wu XP, Liao EY. Insulin-like effects of visfatin/PBEF/Nampt on human osteoblasts. Calcif Tissue Int 2007 80 201-210
28. Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genc H, Erdem G, Gok M, Bingol N, Kilic S, Ozgurtas T, Bingol S. Plasma visfatin/PBEF/Nampt levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 2007 76 24-29
29. Krzyzanowska K, Krugluger W, Mittermayer F, Rahman R, Haider D, Shnawa N, Schernthaner G. Increased visfatin/PBEF/Nampt concentrations in women with gestational diabetes mellitus. Clin Sci (Lond) 2006 110 605-609
30. Chan TF, Chen YL, Chen HH, Lee CH, Jong SB, Tsai EM. Increased plasma visfatin/PBEF/Nampt concentrations in women awith polycystic ovary syndrome. Fertil Steril 2007 88 401-405
31. Sommer G, Garten A, Petzold S, Beck-Sickinger AG, Blher M, Stumvoll M, Fasshauer M. Visfatin/PBEF/Nampt/PBEF/Nampt: Structure, regulation and potential function of a novel adipokine. Clin Sci (Lond) 2008 115 13-23
32. Dahl TB, Yndestad A, Skjelland M, ie E, Dahl A, Michelsen A, Dams JK, Tunheim SH, Ueland T, Smith C, Bendz B, Tonstad S, Gullestad L, Frland SS, Krohg-Srensen K, Russell D, Aukrust P, Halvorsen B. Increased expression of visfatin/PBEF/Nampt in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation. 2007 115 972-980
33. Tsiotra PC, Tsigos C, Yfanti E, Anastasiou E, Vikentiou M, Psarra K, Papasteriades C, Raptis SA. Visfatin/PBEF/Nampt, TNF-alpha and IL-6 mRNA expression is increased in mononuclear cells from type 2 diabetic women. Horm Metab Res 2007 39 758-763
34. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, ORahilly S. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001 50 2199-2202
35. Chen CC, Li TC, Li CI, Liu CS, Wang HJ, Lin CC. Serum resistin level among healthy subjects: relationship to anthropometric and metabolic parameters. Metabolism 2005 54 471-475
36. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, Orlova C, Mantzoros CS. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003 88 4848-4856
37. Ohmori R, Momiyama Y, Kato R, Taniguchi H, Ogura M, Ayaori M, Nakamura H, Ohsuzu F. Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. J Am Coll Cardiol. 2005 46 379-380
38. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005 111 932-939
39. Dez JJ, Iglesias P, Fernndez-Reyes MJ, Aguilera A, Bajo MA, Alvarez-Fidalgo P, Codoceo R, Selgas R. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol (Oxf) 2005 62 242-249
40. Kougias P, Chai H, Lin PH, Yao Q, Lumsden AB, Chen C. Effects of adipocyte-derived cytokines on endothelial functions: implication of vascular disease. J Surg Res 2005 126 121-129